Atezolizumab - Pd-L1 Inhibitor In Non-Small-Cell Lung Cancer

Advanced non-small-cell lung cancer is still a challenging disease. Chemotherapy and EGFR or ALK tyrosine kinase inhibitors are well-established options. Immunotherapy with immune-checkpoint inhibitors significantly improves survival both in first-and second-line treatment. Atezolizumab is one of the novel immunotherapies. This paper presents current data on mechanisms of action and clinical data of atezolizumab in second-line treatment of patients with advanced non-small-cell lung cancer.